Abbott's Xience Xpedition coronary stent wins CE Mark approval in the European Union.
The Chicago-area medical device company said the Xience Xpedition is approved to treat patients with diabetes and requires only 3 months of dual-antiplatelet drug therapy, which Abbott touted as "the shortest duration required for any major drug eluting stent offered in Europe," according to a press release.
Abbott's Xience Xpedition coronary stent wins CE Mark approval in the European Union. Abbott (NYSE:ABT) said its Xience Xpedition coronary stent won CE Mark approval in Europe, with an immediate launch slated for all countries that recognize the mark. News Well, Stent Warsread more